claim: novartis bags mesoblast limited cell death, remestemcel-l for covid-19 ards.
evidence_1: jan 13, 2021 birinapant licensing; avantgen, igm pairs up for anti-sars-cov-2 antibodies; beigene, novartis to co-dvelop tislelizumab; valo raises usd190 m; bluebird bio spins-off jan 12, 2021 parkinson's disease: how close are we to a cure?", "per the agreement, novartis will acquire the exclusive worldwide rights to develop, commercialize and manufacture remestemcel-l for ards and obtain access to an innovative cell-therapy platform with a range of potential applications in severe respiratory conditions and beyond.", 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  "]: dot [@]: at [mhra]: medicines and healthcare products regulatory agency [jcvi]: joint committee for vaccination and immunisation [pmc]: penske media corporation [ covid-19]: coronavirus disease 2019 [covid-19]: coronavirus disease 2019 [v]: view this template [t]: discuss this template [e]: edit this template []: you need to accept this checkbox.", "novartis entered into an exclusive worldwide license and collaboration agreement with mesoblast for the development, commercialization and manufacturing of remestemcel-l for the treatment of acute respiratory distress syndrome (ards), including that associated with covid-19."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )